Richard Appleton
Overview
Explore the profile of Richard Appleton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Messahel S, Bracken L, Appleton R
Open Access Emerg Med
. 2022 Sep;
14:491-506.
PMID: 36158897
Convulsive status epilepticus (CSE) is the most common neurological emergency in children and the second most common neurological emergency in adults. Mortality is low, but morbidity, including neuro-disability, learning difficulties,...
2.
Bacon M, Appleton R, Bangalore H, Brand C, Browning J, Chin R, et al.
Arch Dis Child Educ Pract Ed
. 2022 Jun;
108(1):43-48.
PMID: 35732467
No abstract available.
3.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Health Technol Assess
. 2021 Dec;
25(75):1-134.
PMID: 34931602
Background: Levetiracetam (Keppra, UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran, Eisai Co. Ltd, Tokyo, Japan) are licensed as monotherapy for focal epilepsy, and levetiracetam is increasingly used as a...
4.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Lancet
. 2021 Apr;
397(10282):1375-1386.
PMID: 33838758
Background: Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is...
5.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Lancet
. 2021 Apr;
397(10282):1363-1374.
PMID: 33838757
Background: Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient...
6.
Roper L, Lyttle M, Gamble C, Humphreys A, Messahel S, Lee E, et al.
Emerg Med J
. 2020 Oct;
38(3):191-197.
PMID: 33051276
Background: Key challenges to the successful conduct of The Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) trial were identified at the pre-trial stage. These included...
7.
Roper L, Lyttle M, Gamble C, Humphreys A, Messahel S, Lee E, et al.
Emerg Med J
. 2020 Aug;
38(3):198-204.
PMID: 32862140
Background: Alternatives to prospective informed consent enable the conduct of paediatric emergency and critical care trials. Research without prior consent (RWPC) involves practitioners approaching parents after an intervention has been...
8.
Balabanova S, Taylor C, Sills G, Burnside G, Plumpton C, Smith P, et al.
BMJ Open
. 2020 Aug;
10(8):e040635.
PMID: 32847927
Introduction: Antiepileptic drugs (AEDs) are the mainstay of epilepsy treatment. Over the past 20 years, a number of new drugs have been approved for National Health Service (NHS) use on...
9.
Woolfall K, Roper L, Humphreys A, Lyttle M, Messahel S, Lee E, et al.
Trials
. 2019 Mar;
20(1):181.
PMID: 30898169
Background: EcLiPSE (Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children) is a randomised controlled trial (RCT) in the United Kingdom. Challenges to success include the need to...
10.
Camfield P, Andrade D, Camfield C, Carrizosa-Moog J, Appleton R, Baulac M, et al.
Epilepsy Behav
. 2019 Jan;
93:138-147.
PMID: 30642688
Objective evidence is limited for the value of transition programs for youth with chronic illness moving from pediatric to adult care; however, such programs intuitively "make sense". We describe the...